BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2

Autor: Oezlem Tuereci, Arianne Plaschke, Tompkins Kristin Rachael, Andre P. Heinen, Joshua A. Lees, Stefan Schille, Kena A. Swanson, Deepak Kaushal, Kathrin U. Jansen, Corinna Rosenbaum, Danka Pavliakova, Ugur Sahin, Shannan Hall-Ursone, Rani S. Sellers, Journey Cole, Parag Sahasrabudhe, Stefanie A. Krumm, Ferdia Bates, Stephanie Erbar, Isis Kanevsky, Bianca Saenger, Michal Gazi, Annette B. Vogel, Kathleen M. Brasky, Matthew R. Gutman, Hanna Junginger, Sarah C. Dany, Nicole L. Nedoma, Lena M. Kranz, Camila R. Fontes-Garfias, Julia Schlereth, Shambhunath Choudhary, Andreas A.H. Su, Ramon de la Caridad Gueimil Garcia, Seungil Han, Thorsten Klamp, Ayuko Ota-Setlik, Bonny Gaby Lui, Michael W. Pride, Fulvia Vascotto, Ann-Kathrin Wallisch, Ingrid L. Scully, Stephanie Hein, David Eisel, Charles Tan, Pei Yong Shi, Mathias Vormehr, Philip R. Dormitzer, Olga Gonzalez, Kendra J. Alfson, Thomas Hiller, Bernadette Jesionek, Thomas Ziegenhals, Stephanie Fesser, Jennifer Obregon, Petra Adams-Quack, Matthew C. Griffor, Alptekin Gueler, Yvonne Feuchter, Alexander Muik, Jakob Loschko, Jane Fontenot, Christoph Kroener, Ricardo Carrion, Leyla Fischer, Warren Kalina, Andreas N. Kuhn, Ye Che, Guy Singh, Diana Schneider, Mohan S. Maddur, Kerstin C. Walzer, Tara Ciolino, Ellene H. Mashalidis

A safe and effective vaccine against COVID-19 is urgently needed in quantities sufficient to immunise large populations. We report the preclinical development of two BNT162b vaccine candidates, which contain lipid-nanoparticle (LNP) formulated nucleo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b00b93d3b666e0e3993b1b7ab468149
https://doi.org/10.1101/2020.12.11.421008